Studies and Registries
Access the latest studies, insights, and literature to improve care.
Expertise and clinical evidence
The introduction of new extracorporeal therapies for critically ill patients requires rigorous medical and scientific effort to demonstrate safety, efficacy, and clinical outcome benefits. This foundation is essential for the proper application, acceptance, and recommendation of the therapy as a standard adjunctive treatment, and for securing reimbursement within healthcare systems.
Because of this, we are continually expanding and enhancing the knowledge and clinical evidence supporting our therapies, making this information widely available to our clinical application partners.
-
Multicentric Studies
CytoSorbents has initiated numerous multicentric trials in cardiac surgery, septic shock, and critical care. Published studies validate CytoSorb’s safety and efficacy. Ongoing investigator-initiated trials, some actively recruiting and others completed, continue to confirm its effectiveness. Among others, projects in shock reversal in vasoplegic septic shock (PROCYSS study) and left-ventricular assist device implantation are underway. The STAR-T trial in the USA has now completed. An increase in published clinical data is expected, as several projects are nearing completion or already completed.
CytoSorbents study IDCategoryCountrySitePatient No.StatusRegistrationS18 PROCYSS study Germany 20 260 Recruiting Resource O06 COSMOS Registry International Multiple 3000 Recruiting Resource P01 Pancreatitis Germany Technical University Munich, Hospital Weiden 30 Published Resource CSI01 Cardiopulmonary bypass intraoperative (infective endocarditis / REMOVE) Germany 14 sites 250 Published Resource CT Reg COVID-19 CTC Registry USA Multiple 100 Published Resource S14 Septic Shock (MiHaS) Germany 3 sites 40 Data analysis Resource CSI08 Cardiopulmonary bypass intraoperative UK, Netherlands 2 sites 60 Recruiting Resource STAR Antithrombotic removal registry International Multiple 500 Recruiting Resource STAR-T Cardiopulmonary bypass intraoperative USA Multiple 120 Publication phase Resource CSI01Cardiopulmonary bypass intraoperative (infective endocarditis / REMOVE)Germany14 sites250Published -
Monocenter Studies
Renowned clinics all over the globe are studying the effectiveness of CytoSorbents’ solutions in various hyperinflammatory conditions. Research spans high-risk cardiac surgery on bypass, refractory septic shock, burns, and liver failure. Numerous investigator-initiated trials are in progress, with some recruiting or completed. Ongoing and upcoming projects indicate a continued surge in published evidence on the effectiveness and clinical outcomes of CytoSorb Therapy.
CytoSorbents study IDCategoryCountrySitePatient No.StatusRegistrationTx04 Orthotopic Heart Transplantation Hungary Semmelweis University, Budapest 60 Published Resource SepsAR3 Septic Shock Germany University Medical Centre, Mainz 150 Recruiting Resource S21 Septic Shock Netherlands Nijmegen Radboud UMC 24 Published Resource S19 Septic Shock Germany Hamburg University Hospital Hamburg-Eppendorf, Hamburg 32 Recruiting Resource O930 VA ECMO (cardiogenic shock) Germany Jena University Hospital 54 Recruiting Resource O921 COVID-19 Belgium CHU Brugmann, Brussels 24 Data analysis Resource O03 Cytokine Release Syndrome Germany Hannover Medical School 34 Recruiting Resource EC05 Post arrest requiring eCPR Germany Freiburg University Hospital, Freiburg 20 Published Resource CYTOCOV-19 COVID-19 patients Germany Hamburg University Hospital Hamburg – Eppendorf, Hamburg 24 Published Resource Cyto-HOPE Liver Transplant Italy Papa Giovanni XXIII Hospital, Bergamo 20 Recruiting Resource CSI26 Cardiac Surgery Netherlands LUMC Leiden 36 Recruiting Resource CSI22 Cardiac Surgery Sweden Sahlgrenska University Hospital Gothenburg 20 Published Resource CSI16 Cardiac Surgery Switzerland Dept of Intensive Care Medicine, Bern 54 Recruiting Resource CSI06 Cardiopulmonary bypass intraoperative Germany Nuremberg hospital 40 Publication phase Resource CGS01 Post cardiac arrest Switzerland Centre Hospitalier Universitaire, Vaudois, Lausanne 40 Published Resource S19Septic ShockGermanyHamburg University Hospital Hamburg-Eppendorf, Hamburg32RecruitingEC05Post arrest requiring eCPRGermanyFreiburg University Hospital, Freiburg20PublishedCYTOCOV-19COVID-19 patientsGermanyHamburg University Hospital Hamburg – Eppendorf, Hamburg24PublishedCSI06Cardiopulmonary bypass intraoperativeGermanyNuremberg hospital40Publication phaseCGS01Post cardiac arrestSwitzerlandCentre Hospitalier Universitaire, Vaudois, Lausanne40Published -
The CytoSorb Registries
The COSMOS (CytoSorb TreatMent OF Critically Ill PatientS) registry was opened in mid-2022 and is a company-sponsored international registry designed to provide an infrastructure for the ongoing surveillance of CytoSorb use in real-world critical-care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient selection for CytoSorb and related treatment modalities. Recruitment is ongoing.
The STAR (Safe and Timely Antithrombotic Removal) registry was first registered with ClinicalTrials.gov in Sept 2021 and is a company sponsored multicentric European Registry designed to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents. Recruitment is ongoing.
Voices around the world
Dr. Marianna di Feliciantonio
Milan, ItalyWe improved his state and we helped this patient to the transplantation, and we used the CytoSorb like a bridge for transplant.
Prof. Dorel Sandec
Timisoara, RomaniaWe treated more than 75 patients with CytoSorb® because we realized, we feel, we see, we measure a significant effect on the evolution of the patient.
Dr. Daniela Nickoleit-Bitzenberger
Dortmund, GermanyWithout CytoSorb, things would have been very dicey. We would probably have had to admit him to a special clinic for liver deseases.